Tag: pharmaceuticals

  • Vaccine Developer Awarded Countermeasures Center Contract

    Emergent BioSolutions Inc. in Rockville, Maryland was awarded a contract from Biomedical Advanced Research and Development Authority (BARDA) to establish a development center for medical countermeasures against public health emergencies. BARDA is a division of the U.S. Department of Health and Human Services (HHS). The eight-year contract is valued at $220 million. The agreement will…

  • Report: Few Biotechs Working on Neglected Diseases

    A report by BIO Ventures for Global Health, a not-for-profit organization related to the Biotechnology Industry Organization (BIO), says only about five percent of the world’s biotechnology companies are developing new drugs, vaccines, or diagnostics against neglected diseases. The report, Biotechnology: Bringing Innovation to Neglected Disease Research and Development, is scheduled for release today at…

  • Merck, Ambrx to Partner on Biologics Candidate Development

    Ambrx Inc., a biopharmaceutical company in La Jolla, California, will collaborate with the global pharmaceutical maker Merck, to design and develop biologic drug conjugates, antibodies connected to drug payloads that bind with disease cell targets. The deal has a value of up to $303 million for Ambrx. The agreement gives Merck worldwide rights to develop…

  • Prescription Warning Label Effectiveness Found Limited

    A study by researchers at Michigan State and Kansas State universities has found warning labels on prescription drugs have limited effectiveness due in large part to their inability to get the attention of users. The results of the study appear this week in the online journal PLoS One. The team led by Michigan State packaging…

  • New Process Speeds Multiple Sclerosis Treatment to Trial

    The Myelin Repair Foundation in California says research it has sponsored has moved to clinical trial stage faster than expected due to a model that accelerates the research process. The phase 1 clinical trial, for which enrollment has begun, will test the efficacy of a treatment for multiple sclerosis that repairs myelin through a therapeutic…

  • Blood Disease Start-Up Lands $40.7M in Venture Funding

    Global Blood Therapeutics Inc., a biotechnology company in San Francisco launched today with $40.7 million in funding from venture capital company Third Rock Ventures. The company plans to develop small molecule drugs to treat genetic blood disorders, such as sickle cell disease. The company’s founders include three biomedical researchers from University of California in San…

  • Novo Nordisk, Foundation to Partner on Type 1 Diabetes

    JDRF, a foundation supporting research on type 1 diabetes, and the Danish pharmaceutical company Novo Nordisk will partner on studies of the autoimmune process that plays a key role in type 1 diabetes. Financial details of the collaboration were not disclosed. Type 1 diabetes is sometimes called insulin-dependent, immune-mediated, or juvenile-onset diabetes, although it can…

  • Patent Awarded for Curry Compound as Drug Ingredient

    A patent has been awarded for compounds based on a substance in the spices curry and turmeric, to use in treatments for a number of diseases, including some cancers. Patent number 8,198,323 was awarded yesterday by the U.S. Patent and Trademark Office to nine inventors, and assigned to University of Rochester in New York, University…

  • Five More Pharma Companies Join NIH Drug Extension Project

    A program at National Institutes of Health (NIH) to find new uses for currently tested drugs gained five more pharmaceutical company participants. Abbott, Bristol-Myers Squibb, GlaxoSmithKline, Janssen Pharmaceutical (a division of Johnson & Johnson), and Sanofi will take part in the Discovering New Therapeutic Uses for Existing Molecules program, run by National Center for Advancing…

  • GE Healthcare, CSIRO to Partner on Alzheimer’s Diagnostics

    GE Healthcare, a division of General Electric Company, and CSIRO, Australia’s science agency, will collaborate on the development of imaging tools to better predict people at risk of developing Alzheimer’s disease. CSIRO is the Australian Commonwealth Scientific and Industrial Research Organisation, which is funding the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL).…